148 related articles for article (PubMed ID: 25861016)
1. Effect of Eradication of HCV on Hepatic Venous Pressure Gradient in HIV-Infected Patients With Compensated HCV-Related Cirrhosis.
Sánchez-Conde M; Pérez-Latorre L; Rincón D; Miralles P; Catalina MV; López JC; Bañares R; Berenguer J
J Acquir Immune Defic Syndr; 2015 Aug; 69(4):e142-4. PubMed ID: 25861016
[No Abstract] [Full Text] [Related]
2. Delaying HCV treatment in HIV-positive patients.
Carter M
IAPAC Mon; 2005 May; 11(5):147. PubMed ID: 16201045
[No Abstract] [Full Text] [Related]
3. PegIFN/ribavirin during acute HCV coinfection.
Bernard EJ
IAPAC Mon; 2004 Jul; 10(7):260-1. PubMed ID: 15624247
[No Abstract] [Full Text] [Related]
4. HBV plus HCV, HCV plus HIV, HBV plus HIV.
Park JS; Saraf N; Dieterich DT
Curr Gastroenterol Rep; 2006 Feb; 8(1):67-74. PubMed ID: 16510037
[TBL] [Abstract][Full Text] [Related]
5. Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir.
Moreno A; Quereda C; Montes M; Pérez-Elías MJ; Casado JL; Rodríguez-Sagrado MA; Mateos ML; Dronda F; Bárcena R; Del Campo S; Moreno S
J Acquir Immune Defic Syndr; 2012 Nov; 61(3):e47-9. PubMed ID: 23095936
[No Abstract] [Full Text] [Related]
6. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C.
Arends JE; van Assen S; Stek CJ; Wensing AM; Fransen JH; Schellens IM; Spijkers SN; Mudrikova T; van Baarle D; Sprenger HG; Hoepelman AI
Antivir Ther; 2011; 16(7):979-88. PubMed ID: 22024513
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon α-2a plus ribavirin for decompensated hepatitis C virus-related cirrhosis: relationship between efficacy and cumulative dose.
Xu Y; Qi W; Wang X; Zhao P; Zhang Y; Zhang Q; Qin S; Wang J
Liver Int; 2014 Nov; 34(10):1522-31. PubMed ID: 25453135
[TBL] [Abstract][Full Text] [Related]
9. Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.
Breilh D; Djabarouti S; Trimoulet P; Le Bail B; Dupon M; Ragnaud JM; Fleury H; Saux MC; Thiébaut R; Chêne G; Neau D
J Acquir Immune Defic Syndr; 2009 Nov; 52(3):428-30. PubMed ID: 19858925
[No Abstract] [Full Text] [Related]
10. [Treatment of hepatitis C virus in HIV-positive patients].
Mallolas Masferrer J; Martínez-Rebollar M; Laguno Centeno M
Gastroenterol Hepatol; 2011 Oct; 34(8):558-67. PubMed ID: 21435743
[TBL] [Abstract][Full Text] [Related]
11. Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs?
Franchini M
Hematology; 2006 Jun; 11(3):209-13. PubMed ID: 17325964
[TBL] [Abstract][Full Text] [Related]
12. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
Mukherjee S; Lyden E
Hepatogastroenterology; 2006; 53(70):561-5. PubMed ID: 16995462
[TBL] [Abstract][Full Text] [Related]
13. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
[TBL] [Abstract][Full Text] [Related]
14. HIV & hepatitis C: treatment.
WORLD; 2002 May; (133):4-5. PubMed ID: 12064298
[No Abstract] [Full Text] [Related]
15. Co-infections. German doctors treat hepatitis C early, with some success.
TreatmentUpdate; 2006; 18(5):3-4. PubMed ID: 17209229
[No Abstract] [Full Text] [Related]
16. HIV and hepatitis C co-infection: acute HCV therapy.
Boesecke C; Vogel M
Curr Opin HIV AIDS; 2011 Nov; 6(6):459-64. PubMed ID: 22001891
[TBL] [Abstract][Full Text] [Related]
17. [Outcome of treatment with peg-interferon and ribavirin in HIV-HCV co-infected patients: "real life" single center experience].
Veitsman E; Shahar E; Hassoun G; Lorber M; Kramskay R; Maor C; Pollack S; Baruch Y
Harefuah; 2012 Dec; 151(12):684-7, 721, 720. PubMed ID: 23330260
[TBL] [Abstract][Full Text] [Related]
18. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
[TBL] [Abstract][Full Text] [Related]
19. Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV/HCV patients prior to pegylated interferon and ribavirin.
Moreno A; Bárcena R; Blázquez J; Quereda C; Gil-Grande L; Sánchez J; Moreno L; Perez-Elías MJ; Antela A; Moreno J; del Campo S; Moreno S
Antivir Ther; 2004 Dec; 9(6):1027-30. PubMed ID: 15651761
[TBL] [Abstract][Full Text] [Related]
20. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA
Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
